News Releases Year: - Any -20192018201720162015201420132012 Items per page 102550 02/27/19 Summary ToggleClearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019 PDF Version 02/20/19 Summary ToggleClearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019 PDF Version 02/19/19 Summary ToggleClearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society PDF Version 01/20/19 Summary TogglePresentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose PDF Version 01/02/19 Summary ToggleClearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference PDF Version 12/19/18 Summary ToggleClearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis PDF Version 11/08/18 Summary ToggleClearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update PDF Version 11/07/18 Summary ToggleClearside Biomedical to Participate in Stifel 2018 Healthcare Conference PDF Version 11/05/18 Summary ToggleClearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow PDF Version 11/05/18 Summary ToggleClearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint PDF Version Pagination First page First Previous page Page 1 Current page 2 Page 3 Page 4 Next page Last page Last
